Why are Academics Not Keen on Pharma Funding?
- Less (or no) kudos for industry studies
- Study design often ‘fixed’
- Usually ‘sponsored’ by industry
- Institution keeps all the money
- Study question of limited interest
- Good publications ‘difficult’
- Opportunity cost; less academic research
- Generates ‘conflict of interest’
Raising the Bar for Regulatory Science
- Utilise tried and trusted ‘peer review’ competitive grant award mechanisms
- Promote academic importance of regulatory science
- Stimulate innovation and excellence to create robust regulatory evidence
- Remove direct funding link between industry and academia
- Independent
How?
Suggested Voluntary System:
- EMA decides on the data required to support regulation
- Industry offered the option to have regulatory requirement fulfilled by a voluntary scheme
- EMA partners with an ‘established’ scientific funding body (for example the Wellcome Trust)
Author: Thomas Macdonald, University of Dundee, ENCePP Steering Group
Presented at: ENCePP Plenary Meeting, 24 November 2015